The University of Texas Health Science Center at San Antonio

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

212

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

13 drugs in development

Approved4

Phase 32

Phase 26

Phase 19

Preclinical4

By Therapeutic Area

top 6

Oncology

521%

Metabolic & Endocrine

417%

Cardiovascular

28%

Infectious Disease

28%

Neurology

28%

Ophthalmology

14%

R&D Momentum

74/100

Pipeline Velocity

41/100

Trial Completion Rate

78/100

Pipeline Concentration

13/100

Pipeline Freshness

65/100

Strategic Signals

↗Active in Ophthalmology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Recruiting

Transcranial Magnetic Stimulation as Treatment for Persistent PTSD in Texas Youth

Jul 14, 2026

Completed

Evaluation of KIOS in a 12-week Randomized Controlled Trial

Jul 1, 2026

Completed

A Pilot Study to Evaluate the Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients With Curative Resections.

Jul 1, 2026

Active, not recruiting

Targeting Chronic Pain in Primary Care Settings Using Behavioral Health Consultants, A Randomized Pragmatic Trial

Earlier

Jun 27, 2026TrialProject MARCH: Multisite Advancement of Research on Chronic Posttraumatic Headache

Jun 27, 2026TrialRURAL Heart and Lung Study

Jun 26, 2026TrialThe Effects of Stellate Ganglion Block on Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for Posttraumatic Stress Disorder (PTSD)

Jun 25, 2026TrialEvaluation of Tooth Whitening Efficacy of GuruNanda Oil Pulling Oral Rinse.

3 more events

Jun 24, 2026TrialContingency Management Using Deposit Contract to Reduce Drinking

Jun 24, 2026TrialA Senior Center-Based Multilevel Lifestyle Intervention to Improve Physical Function in Older Adults With Type 2 Diabetes (RESILIENT)

Jun 24, 2026TrialPhase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(2 drugs)

—

Cardiovascular(2 drugs)

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(4 drugs)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(5 drugs)

—

Oncology(5 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Rare Disease(1 drug)

—

Rare Disease(1 drug)

Unknown / Other(4 drugs)

—

Unknown / Other(4 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)